Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma Case report and literature review

被引:12
|
作者
Oezdirik, Burcin [1 ]
Jost-Brinkmann, Fabian [1 ]
Savic, Lynn Jeanette [2 ,3 ]
Mohr, Raphael [1 ]
Tacke, Frank [1 ]
Ploner, Christoph J. [4 ]
Roderburg, Christoph [1 ,5 ]
Mueller, Tobias [1 ]
机构
[1] Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Dept Diagnost & Intervent Radiol, Berlin, Germany
[3] Berlin Inst Hlth BIH, Berlin, Germany
[4] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[5] Heinrich Heine Univ Dusseldorf, Fac Med, Univ Hosp Dusseldorf, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
关键词
atezolizumab; bevacizumab; case report; encephalitis; hepatocellular carcinoma; immune checkpoint-inhibitor; SORAFENIB;
D O I
10.1097/MD.0000000000026377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth factor (VEGF) antibody, represents a promising novel first-line therapy in patients with advanced hepatocellular carcinoma (HCC). Despite favorable safety data, serious adverse events have been described. However, central nervous system complications such as encephalitis have rarely been reported. We present the case of a 70-year-old woman with hepatitis C virus (HCV)-related liver cirrhosis and advanced HCC who developed severe encephalitis after only one cycle of atezolizumab/bevacizumab. Patient concerns: Ten days after administration, the patient presented with confusion, somnolence, and emesis. Within a few days, the patient's condition deteriorated, and mechanical ventilation became necessary. Diagnosis: Cerebrospinal fluid (CSF) analysis showed increased cell count and elevated protein values. Further work-up revealed no signs of an infectious, paraneoplastic, or other autoimmune cause. Intervention: Suspecting an atezolizumab/bevacizumab-related encephalitis, we initiated a high-dose steroid pulse therapy as well as repeated plasmapheresis, which resulted in clinical improvement and remission of CSF abnormalities. Outcome: Despite successful weaning and transfer to a rehabilitation ward, the patient died of progressive liver cancer 76 days after initial treatment with atezolizumab/bevacizumab, showing no response. Conclusion: This case illustrates that rapid immunosuppressive treatment with prednisolone can result in remission even of severe encephalitis. We discuss this case in the context of available literature and previously reported cases of atezolizumab-induced encephalitis in different tumor entities, highlighting the diagnostic challenges in oncologic patients treated with immune checkpoint-inhibitors.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
    Cappuyns, Sarah
    Pique-Gili, Marta
    Esteban-Fabro, Roger
    Philips, Gino
    Pinyol, Roser
    Vandecaveye, Vincent
    Abril-Fornaguera, Jordi
    Haber, Philipp
    Verslype, Chris
    Van Cutsem, Eric
    Lambrechts, Diether
    Villanueva, Augusto
    Dekervel, Jeroen
    Llovet, Josep M.
    HEPATOLOGY, 2023, 78 : S1871 - S1872
  • [22] Evans’ syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
    Masanori Fukushima
    Kazuaki Tajima
    Ryu Sasaki
    Yasuhiko Nakao
    Kosuke Takahashi
    Eisuke Ozawa
    Satoshi Miuma
    Takeharu Kato
    Hisamitsu Miyaaki
    Kazuhiko Nakao
    Clinical Journal of Gastroenterology, 2023, 16 : 402 - 406
  • [23] Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
    Fukushima, Masanori
    Tajima, Kazuaki
    Sasaki, Ryu
    Nakao, Yasuhiko
    Takahashi, Kosuke
    Ozawa, Eisuke
    Miuma, Satoshi
    Kato, Takeharu
    Miyaaki, Hisamitsu
    Nakao, Kazuhiko
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 402 - 406
  • [24] Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
    Sato, Shun
    Aoki, Taku
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Mori, Shozo
    Iso, Yukihiro
    Nemoto, Takehiko
    Onishi, Toshihiko
    Iijima, Makoto
    Ishida, Kazuyuki
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (02) : 292 - 299
  • [25] Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
    Shun Sato
    Taku Aoki
    Takatsugu Matsumoto
    Takayuki Shiraki
    Shozo Mori
    Yukihiro Iso
    Takehiko Nemoto
    Toshihiko Onishi
    Makoto Iijima
    Kazuyuki Ishida
    Clinical Journal of Gastroenterology, 2024, 17 : 292 - 299
  • [26] Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
    Ai, Haidong
    Gong, Ting
    Ma, Yongbiao
    Ma, Guixu
    Ding, Wei
    Ding, Weibao
    Wang, Wenjuan
    Zhao, Xuelin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] Bevacizumab-Induced Esophageal Perforation: A Case Report
    Abidian, Mohamed Modar
    Nath, Anand
    Shafa, Shervin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S982 - S983
  • [28] A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review
    Fuji, Takahiro
    Arai, Jun
    Otoyama, Yumi
    Nio, Yuta
    Sugiura, Ikuya
    Nakajima, Yoko
    Kajiwara, Atsushi
    Ichikawa, Yuki
    Uozumi, Shojiro
    Shimozuma, Yuu
    Uchikoshi, Manabu
    Sakaki, Masashi
    Nozawa, Hisako
    Momo, Kenji
    Sasaki, Tadanori
    Yoshida, Hitoshi
    ONCOTARGETS AND THERAPY, 2022, 15 : 1281 - 1288
  • [29] Transthyretin Cardiac Amyloidosis Mimicking Immune Checkpoint-Induced Myocarditis in a Patient Treated with Atezolizumab and Bevacizumab for Advanced Hepatocellular Carcinoma: A Case Report
    Le Bras, Pierrine
    Plard, Louise
    Le Gouill, Christele
    Piriou, Nicolas
    Touchefeu, Yann
    CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 967 - 973
  • [30] Atezolizumab and Bevacizumab in Hepatocellular Carcinoma REPLY
    Finn, Richard S.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07): : 695 - 695